secwatch.observer — SEC 8-K summary
======================================

Issuer:     ABBOTT LABORATORIES (ABT)
CIK:        0000001800
Form:       8-K
Filed at:   2022-10-19T23:59:59+00:00
Accession:  0001628280-22-026588
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Abbott posts Q3 adj. EPS $1.15, revenue $10.4B; raises full-year EPS guidance
-----------------------------------------------------------------------------

- Q3 GAAP EPS $0.81, adjusted EPS $1.15; reported sales -4.7%, organic +1.3%.
- Raises FY2022 adjusted EPS guidance to $5.17-$5.23; GAAP guidance $3.75-$3.81.
- U.S. Medical Devices sales +11.3%; FreeStyle Libre revenues ~$1.0B in Q3.
- COVID testing-related sales $1.7B in Q3 vs $1.9B a year ago; full-year outlook $7.8B.
- Restarted infant formula production at Sturgis plant; quarterly dividend $0.47/share payable Nov. 15.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1800/000162828022026588/0001628280-22-026588-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1800/000162828022026588/abt-20221019.htm
  HTML page:      https://secwatch.observer/filing/0001628280-22-026588

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer